Eric Coldwell
Stock Analyst at Baird
(3.78)
# 777
Out of 5,005 analysts
188
Total ratings
60%
Success rate
5.44%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Outperform | $9 → $14 | $9.45 | +48.15% | 9 | Sep 3, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $222 → $224 | $193.89 | +15.53% | 22 | Sep 2, 2025 | |
| DGX Quest Diagnostics | Downgrades: Neutral | $194 | $179.33 | +8.18% | 11 | Aug 25, 2025 | |
| PINC Premier | Maintains: Neutral | $22 → $27 | $27.90 | -3.21% | 9 | Aug 20, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $197 → $203 | $154.46 | +31.43% | 13 | Aug 13, 2025 | |
| OMI Owens & Minor | Maintains: Outperform | $10 → $7 | $4.76 | +47.06% | 19 | Aug 12, 2025 | |
| LH Labcorp Holdings | Maintains: Outperform | $290 → $302 | $276.94 | +9.05% | 14 | Jul 25, 2025 | |
| MEDP Medpace Holdings | Maintains: Neutral | $313 → $490 | $532.49 | -7.98% | 19 | Jul 23, 2025 | |
| IQV IQVIA Holdings | Maintains: Neutral | $159 → $196 | $206.63 | -5.14% | 18 | Jul 23, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $118 → $140 | $177.33 | -21.05% | 14 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $16 | $9.09 | +76.02% | 10 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $531 → $688 | $738.06 | -6.78% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $59.28 | -24.09% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $77.49 | -14.83% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $1.62 | +2,739.51% | 4 | Nov 10, 2017 |
Fortrea Holdings
Sep 3, 2025
Maintains: Outperform
Price Target: $9 → $14
Current: $9.45
Upside: +48.15%
ICON Public Limited Company
Sep 2, 2025
Maintains: Outperform
Price Target: $222 → $224
Current: $193.89
Upside: +15.53%
Quest Diagnostics
Aug 25, 2025
Downgrades: Neutral
Price Target: $194
Current: $179.33
Upside: +8.18%
Premier
Aug 20, 2025
Maintains: Neutral
Price Target: $22 → $27
Current: $27.90
Upside: -3.21%
Cardinal Health
Aug 13, 2025
Maintains: Outperform
Price Target: $197 → $203
Current: $154.46
Upside: +31.43%
Owens & Minor
Aug 12, 2025
Maintains: Outperform
Price Target: $10 → $7
Current: $4.76
Upside: +47.06%
Labcorp Holdings
Jul 25, 2025
Maintains: Outperform
Price Target: $290 → $302
Current: $276.94
Upside: +9.05%
Medpace Holdings
Jul 23, 2025
Maintains: Neutral
Price Target: $313 → $490
Current: $532.49
Upside: -7.98%
IQVIA Holdings
Jul 23, 2025
Maintains: Neutral
Price Target: $159 → $196
Current: $206.63
Upside: -5.14%
Charles River Laboratories International
May 8, 2025
Maintains: Neutral
Price Target: $118 → $140
Current: $177.33
Upside: -21.05%
Feb 27, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $9.09
Upside: +76.02%
Nov 7, 2024
Upgrades: Outperform
Price Target: $531 → $688
Current: $738.06
Upside: -6.78%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $59.28
Upside: -24.09%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $77.49
Upside: -14.83%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $1.62
Upside: +2,739.51%